Figure 4
Characterization of cyclin D1− MCL patients according to their genetic and molecular features. (A) The genomic complexity is illustrated with bar plots at the top of the panels, reflecting the number of alterations for each patient. The plots below indicate the SOX11 expression and the presence of CCND2 translocations. Orange, SOX11+ MCL; brown: SOX11− MCL; light blue, CCND2 translocation–positive MCL; and dark blue, CCND2 translocation–negative MCL. The status of CDKN2A, ATM, and TP53 genes according to aCGH and SNP-array data are indicated by color (black, not altered; green, loss; blue, homozygous loss; green/orange, loss and mutation; and gray, unknown). (B) Kaplan-Meier estimates of OS for MCL cyclin D1− patients according to 17p status (17p altered vs 17p not altered). D indicates dead.

Characterization of cyclin D1 MCL patients according to their genetic and molecular features. (A) The genomic complexity is illustrated with bar plots at the top of the panels, reflecting the number of alterations for each patient. The plots below indicate the SOX11 expression and the presence of CCND2 translocations. Orange, SOX11+ MCL; brown: SOX11 MCL; light blue, CCND2 translocation–positive MCL; and dark blue, CCND2 translocation–negative MCL. The status of CDKN2A, ATM, and TP53 genes according to aCGH and SNP-array data are indicated by color (black, not altered; green, loss; blue, homozygous loss; green/orange, loss and mutation; and gray, unknown). (B) Kaplan-Meier estimates of OS for MCL cyclin D1 patients according to 17p status (17p altered vs 17p not altered). D indicates dead.

Close Modal

or Create an Account

Close Modal
Close Modal